- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01529580
School-Age Children With Autism With Limited Expressive Language Skills
School-Age Children With Autism With Limited Expressive Language Skills: An Intervention Study
This project will address a major challenge to the field of autism research: improving expressive communication in children with autism who have reached school age but have not acquired functional spoken language (non-verbal school aged children with autism; NVSACA).
Fifteen children who completed the RO1 ICAN intervention (NCT01018407) at the Kennedy Krieger site and follow-up testing but continue to have minimal functional spoken language will be participants in this study. After eligibility is established, participants will be randomly assigned to a baseline duration of one week, two weeks or three weeks before the start of active treatment. Once the baseline duration is completed, participants begin active treatment one hour of intervention three days per week in the participants' school setting. In month 2, weekly teacher trainings begin. In month 5, weekly parent trainings begin to improve the child's generalization of skills and teach parents the strategies implemented in their child's treatment. Post-baseline and post-treatment assessments will be completed in the lab at a time that is convenient for the participants' families.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21211
- Kennedy Krieger Institute
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Diagnosis of autism by a licensed psychologist or board certified developmental pediatrician, or child and adolescent psychiatrist, confirmed by the Autism Diagnostic Observation Schedule (ADOS; Lord, Rutter, DiLavore, & Risi, 1999)
- Chronological age between 4.0 years and 7 years, 11 months
- Reynell developmental score ≤ 24 months, ADOS A1 score of 2, 3 or 8
- Nonverbal IQ of ≥ 40 (Leiter International Performance Scale-Revised (Leiter-R), Roid & Miller, 2007)
- Children have participated in and completed follow-up testing for the ICAN study.
Exclusion Criteria:
- Major medical conditions other than autism (e.g., genetic disorders [e.g., Fragile X, Down syndrome, tuberous sclerosis], blindness or deafness, and motor disabilities such as cerebral palsy;
- Uncontrolled seizures;
- Self-injurious behavior or moderate to severe aggression.
- Children in foster care.
- Children who are exposed to < 50% English throughout their typical day.
- Children currently participating in another intervention/treatment study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: 1 Week Basline Prior to Intervention
If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist.
In this case, the duration is 1 week before your child begins active treatment with their interventionist.
|
The intervention has 3 components:
|
|
Experimental: 2 Week Basline Prior to Intervention
If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist.
In this case, the duration is 2 weeks before your child begins active treatment with their interventionist.
|
The intervention has 3 components:
|
|
Experimental: 3 Week Basline Prior to Intervention
If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist.
In this case, the duration is 3 weeks before your child begins active treatment with their interventionist.
|
The intervention has 3 components:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Baseline Spontaneous Language
Zeitfenster: Weekly throughout the 5 month intervention (baseline and 5 months)
|
The number of unprompted spontaneous language during a 15min play sample.
|
Weekly throughout the 5 month intervention (baseline and 5 months)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Change in Baseline Autism Diagnostic Observation Schedule
Zeitfenster: 5 months into treatment (at completion of intervention)
|
5 months into treatment (at completion of intervention)
|
|
Change in Baseline Reynell
Zeitfenster: 5 months into treatment (at completion of intervention)
|
5 months into treatment (at completion of intervention)
|
|
Changes in Baseline Early Social Communication Scales (ESCS)
Zeitfenster: 5 months into treatment (at completion of intervention) and 6 months following the completion of the intervention
|
5 months into treatment (at completion of intervention) and 6 months following the completion of the intervention
|
|
Changes in Baseline Structured Play Assessment
Zeitfenster: 5 months into treatment (at completion of intervention) and 6 months following the completion of the intervention
|
5 months into treatment (at completion of intervention) and 6 months following the completion of the intervention
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- NA_00049467
- 3R01MH085048-03S1 (US NIH Stipendium/Vertrag)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Autismus-Spektrum-Störung
-
Kaleido BiosciencesBeendetVancomycin-resistente Enterococcus-, Extended-Spectrum-Beta-Lactamase-produzierende Enterobacteriaceae- oder Carbapenem-resistente Enterobacteriaceae-Kolonisierte PersonenVereinigte Staaten
-
University of BordeauxUnbekanntAssoziation von Darmmikrobiota mit ESBL-E-Kolonisierung und nachfolgender ESBL-E-Infektion (Microbe)Kritische Krankheit | Mikrobielle Besiedlung | Extended Spectrum Beta-Lactamase produzierende BakterieninfektionFrankreich
-
Chinese PLA General HospitalNoch keine RekrutierungNeuromyelitis Optica Spectrum -Erkrankung (NMOSD)China
-
University Hospital, Basel, SwitzerlandGebert Rüf-StiftungAktiv, nicht rekrutierendExtended Spectrum Beta-Lactamasen (ESBL) E. ColiSchweiz
-
Hospices Civils de LyonAbgeschlossenNeuromyelitis-Optica-Spektrum-Erkrankungen | Neuromyelitis optica Spectrum Related DisordersFrankreich
-
The Methodist Hospital Research InstituteM.D. Anderson Cancer Center; National Institute of Allergy and Infectious Diseases... und andere MitarbeiterRekrutierungAntibiotikaresistente Infektion | Clostridium difficile | Resistenz gegen antimikrobielle Medikamente | Carbapenem-resistente Enterobacteriaceae-Infektion | Vancomycin-resistente Enterokokken-Infektion | Vancomycin-resistente Enterokokken-Infektion | Carbapenem-resistente bakterielle Infektion | Extended Spectrum Beta-Lactamase produzierende BakterieninfektionVereinigte Staaten
-
Centre Hospitalier Universitaire VaudoisAbgeschlossenStevens-Johnson-Syndrom Toxic Epidermal Necrolysis Spectrum
-
Fondazione Policlinico Universitario Agostino Gemelli...Aktiv, nicht rekrutierendImpfung | Generalisierte Myasthenia gravis | Komplementsystem | Neuromyelitis Optica Spectrum -Erkrankung (NMOSD)Italien
-
Wuhan Union Hospital, ChinaNanjing Legend Biotech Co.RekrutierungMyasthenia gravis | Multiple Sklerose (MS) | Neuromyelitis Optica Spectrum -Erkrankung (NMOSD) | Anti-Myelin-Oligodendrozyten-Glykoprotein-Igg-assoziierte Störungen (Mogad)China
-
National Taiwan University HospitalUnbekanntChronische Graft-versus-Host-Krankheit | Sjögren-Syndrom | Schleimhautpemphigoid | Vernarbende Konjunktivitis | Stevens-Johnson-Syndrom Toxic Epidermal Necrolysis Spectrum | Verätzung des AugesTaiwan